Aethlon Medical agrees to merge with North Immunology and plans $180 million raise
Pulse2.com reports that the planned financing is intended to advance North’s atopic dermatitis drug NOR-101 through multiple clinical readouts.
TLDR
Aethlon Medical has entered into a definitive agreement for an all-stock merger with privately held biotech North Immunology, Pulse2.com reports. Alongside the merger, a planned $180 million private placement is intended to fund development of North’s lead atopic dermatitis program, NOR-101, through multiple clinical readouts. The publisher describes the financing as oversubscribed.
Combined views
38
1 Source, first seen ago